A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 DART® Protein in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory Metastatic Colorectal Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 20 Jan 2019
At a glance
- Drugs INCMGA 0012 (Primary) ; MGD 007 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors MacroGenics
- 15 Nov 2018 Planned number of patients changed from 104 to 52.
- 31 May 2018 Status changed from not yet recruiting to recruiting.
- 09 May 2018 Status changed from planning to not yet recruiting.